Repligen Corporation (NASDAQ:RGEN) has been given a consensus recommendation of “Buy” by the eight analysts that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $46.00.

RGEN has been the topic of a number of research reports. TheStreet raised shares of Repligen Corporation from a “c+” rating to a “b-” rating in a report on Friday, August 11th. Zacks Investment Research raised shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Saturday, August 12th. BidaskClub raised shares of Repligen Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $40.00 price target on shares of Repligen Corporation in a report on Thursday, October 19th. Finally, William Blair initiated coverage on shares of Repligen Corporation in a report on Friday, July 21st. They issued an “outperform” rating on the stock.

Shares of Repligen Corporation (NASDAQ:RGEN) opened at $34.72 on Monday. The company has a quick ratio of 10.29, a current ratio of 11.87 and a debt-to-equity ratio of 0.51. The company has a market cap of $1,512.79, a P/E ratio of 59.87, a P/E/G ratio of 2.31 and a beta of 1.05. Repligen Corporation has a 1-year low of $28.48 and a 1-year high of $46.81.

Repligen Corporation (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.04. The company had revenue of $36.58 million for the quarter, compared to analysts’ expectations of $35.69 million. Repligen Corporation had a net margin of 16.93% and a return on equity of 11.78%. Repligen Corporation’s revenue was up 48.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.08 EPS. analysts expect that Repligen Corporation will post 0.6 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/12/repligen-corporation-rgen-given-average-recommendation-of-buy-by-analysts.html.

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in Repligen Corporation by 3.7% in the 2nd quarter. BlackRock Inc. now owns 4,834,853 shares of the biotechnology company’s stock valued at $200,355,000 after buying an additional 170,551 shares in the last quarter. TimesSquare Capital Management LLC grew its stake in Repligen Corporation by 19.8% in the 2nd quarter. TimesSquare Capital Management LLC now owns 2,361,270 shares of the biotechnology company’s stock valued at $97,851,000 after buying an additional 390,545 shares in the last quarter. Vanguard Group Inc. grew its stake in Repligen Corporation by 9.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,984,393 shares of the biotechnology company’s stock valued at $82,233,000 after buying an additional 175,191 shares in the last quarter. Conestoga Capital Advisors LLC grew its stake in Repligen Corporation by 12.5% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,453,232 shares of the biotechnology company’s stock valued at $55,688,000 after buying an additional 161,427 shares in the last quarter. Finally, FMR LLC grew its stake in Repligen Corporation by 6.2% in the 2nd quarter. FMR LLC now owns 1,334,090 shares of the biotechnology company’s stock valued at $55,285,000 after buying an additional 78,060 shares in the last quarter. Institutional investors and hedge funds own 96.47% of the company’s stock.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.